Geode Capital Management LLC Grows Stock Position in 23andMe Holding Co. (NASDAQ:ME)

Geode Capital Management LLC lifted its stake in 23andMe Holding Co. (NASDAQ:ME) by 0.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,246,093 shares of the company’s stock after buying an additional 28,252 shares during the period. Geode Capital Management LLC owned approximately 0.17% of 23andMe worth $1,476,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC grew its stake in shares of 23andMe by 410.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock worth $35,000 after purchasing an additional 71,204 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of 23andMe in the second quarter worth about $43,000. Levin Capital Strategies L.P. bought a new stake in shares of 23andMe in the second quarter worth about $61,000. AQR Capital Management LLC grew its stake in shares of 23andMe by 145.8% in the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock worth $174,000 after purchasing an additional 263,468 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 23andMe in the second quarter worth about $203,000. Hedge funds and other institutional investors own 36.10% of the company’s stock.

23andMe Price Performance

NASDAQ ME opened at $3.84 on Friday. The stock has a market capitalization of $100.29 million, a PE ratio of -0.15 and a beta of 1.14. 23andMe Holding Co. has a 1 year low of $2.65 and a 1 year high of $16.52. The business’s 50-day moving average is $3.62 and its 200 day moving average is $5.83.

23andMe (NASDAQ:ME) last posted its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter. The business had revenue of $44.07 million during the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.